[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgmt3WG-Co2Za9kODiDPNSoWd_-yL_thVB6_AR83XT70":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":36,"phaseBuckets":47,"rows":54},"New York University",[4,6,7],"New York University Abu Dhabi","New York University Cancer Institute",119,false,40,3,62470,2,111,[16,19,22,25,28,30,32,34],{"name":17,"count":18},"Depression",7,{"name":20,"count":21},"Speech Sound Disorder",6,{"name":23,"count":24},"HIV",5,{"name":26,"count":27},"HIV Infections",4,{"name":29,"count":27},"HIV\u002FAIDS",{"name":31,"count":11},"Dental Fear",{"name":33,"count":11},"Childhood Apraxia of Speech",{"name":35,"count":11},"Psychosis",[37,42],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT06655454","Supplemental Postoperative Bupivacaine Following Non-Surgical Endodontic Treatment","2026-06-30","Supplemental Postoperative Bupivacaine",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT06598397","Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care","2028-06-30","Combination NRT",[48,49,50,51,52,53],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[55,80,104,130,160,185,213,240,258,276],{"intervention":46,"totalTrials":56,"cells":57},1,{"EARLY_PHASE1":58,"PHASE1":61,"PHASE2":63,"PHASE3":65,"PHASE4":67,"NA":78},{"trials":59,"activeCount":60},[],0,{"trials":62,"activeCount":60},[],{"trials":64,"activeCount":60},[],{"trials":66,"activeCount":60},[],{"trials":68,"activeCount":56,"soonestReadout":45},[69],{"nctId":43,"briefTitle":44,"status":70,"phases":71,"primaryCompletion":45,"completion":45,"start":72,"enrollment":73,"conditions":74,"interventions":77},"RECRUITING",[52],"2024-10-18",500,[75,76],"Human Immunodeficiency Virus (HIV)","Smoking Cessation",[46],{"trials":79,"activeCount":60},[],{"intervention":41,"totalTrials":56,"cells":81},{"EARLY_PHASE1":82,"PHASE1":84,"PHASE2":86,"PHASE3":98,"PHASE4":100,"NA":102},{"trials":83,"activeCount":60},[],{"trials":85,"activeCount":60},[],{"trials":87,"activeCount":56,"soonestReadout":40},[88],{"nctId":38,"briefTitle":39,"status":70,"phases":89,"primaryCompletion":40,"completion":90,"start":91,"enrollment":92,"conditions":93,"interventions":97},[50],"2026-12-31","2024-11-01",150,[94,95,96],"Pain Assessment","Quality of Life (QOL)","Analgesic Use",[41],{"trials":99,"activeCount":60},[],{"trials":101,"activeCount":60},[],{"trials":103,"activeCount":60},[],{"intervention":105,"totalTrials":56,"cells":106},"nicotine transdermal system",{"EARLY_PHASE1":107,"PHASE1":109,"PHASE2":111,"PHASE3":113,"PHASE4":126,"NA":128},{"trials":108,"activeCount":60},[],{"trials":110,"activeCount":60},[],{"trials":112,"activeCount":60},[],{"trials":114,"activeCount":60},[115],{"nctId":116,"briefTitle":117,"status":118,"phases":119,"primaryCompletion":120,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},"NCT00067158","Smoking Cessation Treatment With Transdermal Nicotine Replacement Therapy - 1","COMPLETED",[51],"2004-07","2003-04",585,[124],"Tobacco Use Disorder",[105],{"trials":127,"activeCount":60},[],{"trials":129,"activeCount":60},[],{"intervention":131,"totalTrials":56,"cells":132},"RCT-SV",{"EARLY_PHASE1":133,"PHASE1":135,"PHASE2":137,"PHASE3":139,"PHASE4":156,"NA":158},{"trials":134,"activeCount":60},[],{"trials":136,"activeCount":60},[],{"trials":138,"activeCount":60},[],{"trials":140,"activeCount":60},[141],{"nctId":142,"briefTitle":143,"status":144,"phases":145,"primaryCompletion":146,"completion":147,"start":148,"enrollment":149,"conditions":150,"interventions":155},"NCT05256667","Comparison Between RCT in Single and Two Visits, With and Without Intracanal Dressing, in Apical Repair","UNKNOWN",[50,51],"2024-03-28","2024-05-28","2021-10-02",210,[151,152,153,154],"Teeth, Endodontically-Treated","Tooth, Nonvital","Periapical Periodontitis, Chronic Nonsuppurative","Periapical Granuloma",[131],{"trials":157,"activeCount":60},[],{"trials":159,"activeCount":60},[],{"intervention":161,"totalTrials":56,"cells":162},"thalidomide",{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":179,"PHASE4":181,"NA":183},{"trials":164,"activeCount":60},[],{"trials":166,"activeCount":60},[],{"trials":168,"activeCount":60},[169],{"nctId":170,"briefTitle":171,"status":118,"phases":172,"completion":173,"start":174,"conditions":175,"interventions":178},"NCT00006005","Thalidomide in Treating Patients With Gynecologic Sarcomas",[50],"2006-08","2000-09",[176,177],"Endometrial Cancer","Sarcoma",[161],{"trials":180,"activeCount":60},[],{"trials":182,"activeCount":60},[],{"trials":184,"activeCount":60},[],{"intervention":186,"totalTrials":56,"cells":187},"PrEP",{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":189,"activeCount":60},[],{"trials":191,"activeCount":60},[],{"trials":193,"activeCount":60},[],{"trials":195,"activeCount":60},[],{"trials":197,"activeCount":60},[],{"trials":199,"activeCount":60},[200],{"nctId":201,"briefTitle":202,"status":118,"phases":203,"primaryCompletion":204,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":212},"NCT04325555","Pre-exposure Prophylaxis: A Miracle Drug or a Moral Hazard",[],"2020-03-15","2020-01-20",2647,[208,209,210,211],"Syphilis","Chlamydia","Gonorrhea","Sexually Transmitted Diseases",[186],{"intervention":214,"totalTrials":56,"cells":215},"Cervitec chlorhexidine varnish",{"EARLY_PHASE1":216,"PHASE1":218,"PHASE2":220,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":217,"activeCount":60},[],{"trials":219,"activeCount":60},[],{"trials":221,"activeCount":60},[],{"trials":223,"activeCount":60},[],{"trials":225,"activeCount":60},[],{"trials":227,"activeCount":60},[228],{"nctId":229,"briefTitle":230,"status":118,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT00066040","Prevention of Transmission of Bacteria That Cause Cavities From Mothers to Their Children",[53],"2006-01","2001-01",280,[236],"Caries, Dental",[214,238,239],"Duraphat fluoride varnish","xylitol gum from Fennobon, Finland",{"intervention":238,"totalTrials":56,"cells":241},{"EARLY_PHASE1":242,"PHASE1":244,"PHASE2":246,"PHASE3":248,"PHASE4":250,"NA":252},{"trials":243,"activeCount":60},[],{"trials":245,"activeCount":60},[],{"trials":247,"activeCount":60},[],{"trials":249,"activeCount":60},[],{"trials":251,"activeCount":60},[],{"trials":253,"activeCount":60},[254],{"nctId":229,"briefTitle":230,"status":118,"phases":255,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":256,"interventions":257},[53],[236],[214,238,239],{"intervention":239,"totalTrials":56,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":270},{"trials":261,"activeCount":60},[],{"trials":263,"activeCount":60},[],{"trials":265,"activeCount":60},[],{"trials":267,"activeCount":60},[],{"trials":269,"activeCount":60},[],{"trials":271,"activeCount":60},[272],{"nctId":229,"briefTitle":230,"status":118,"phases":273,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":274,"interventions":275},[53],[236],[214,238,239],{"intervention":277,"totalTrials":56,"cells":278},"Pre-Exposure Prophylaxis",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":289},{"trials":280,"activeCount":60},[],{"trials":282,"activeCount":60},[],{"trials":284,"activeCount":60},[],{"trials":286,"activeCount":60},[],{"trials":288,"activeCount":60},[],{"trials":290,"activeCount":60},[291],{"nctId":292,"briefTitle":293,"status":118,"phases":294,"primaryCompletion":295,"completion":295,"start":296,"enrollment":297,"conditions":298,"interventions":301},"NCT01571128","Gender-Specific Combination HIV Prevention for Youth in High Burden Settings (MP3-Youth)",[53],"2016-03-23","2014-11",1215,[23,299,300],"Adolescent Behavior","Gender",[277]]